New vaccines for developing countries: will it be feast or famine?

Area of Science:

• Public Health
• Vaccinology
• Health Economics

Background:

• The Pan American Health Organization (PAHO) Revolving Fund has a 30-year history of supplying essential vaccines across Latin America and the Caribbean.
• The Fund's efforts were instrumental in controlling and eradicating major childhood diseases like measles and polio.
• This success has significantly improved child survival rates in the region.

Purpose of the Study:

• To examine the challenges faced by the PAHO Revolving Fund in procuring new, high-cost vaccines.
• To explore the need for innovative financial mechanisms to ensure affordability of new vaccines.
• To assess the potential impact of bypassing the Revolving Fund on regional health equity.

Main Methods:

• Review of the operational history and financial mechanisms of the PAHO Revolving Fund.
• Analysis of vaccine procurement trends and pricing for traditional versus new vaccine generations.
• Assessment of the economic implications for national immunization programs in Latin America and the Caribbean.

Main Results:

• The PAHO Revolving Fund has a proven track record in vaccine procurement and distribution.
• New vaccines for human papillomavirus, rotavirus, and pneumococcal disease are significantly more expensive than traditional vaccines.
• Current financial models may be insufficient to cover the costs of these new essential vaccines.

Conclusions:

• Innovative financial strategies are necessary for the PAHO Revolving Fund to procure next-generation vaccines.
• Maintaining access to these new vaccines is critical for sustained public health gains in the region.
• Failure to adapt financial mechanisms could jeopardize regional health security, particularly for vulnerable populations.